Safety Advantages No increase in hematocrit or hemoglobin: Unlike EPO, ARA-290 does not stimulate red blood cell production, greatly reducing the risk of polycythemia, thrombosis, or high blood pressure
While some patients experience improvement, others find these symptoms unchanged despite significant overall weight reduction
Only a handful of human studies exist
The exact dose is currently unknown, but it is expected to follow a dosing schedule similar to other weight loss injections, starting at a low dose and gradually increasing to a maximum maintenance dose
Free Radic Biol Med 1999
Specifically, type 2 diabetes in midlife is associated with greater tau pathology later in life but not with amyloid- pathology as measured through positron emission tomography (PET) [53, 56]